Epilepsy is common in patients with intellectual disabilities. 1 More than 30% of these patients develop seizures, 2 with a prevalence of up to 50% in institutionalized patients. 1 Epilepsy in these patients is often characterized by multiple concurrent seizure types [2] [3] [4] [5] and its severity increases with the severity of the mental handicap, probably reflecting the amount of underlying brain damage. Treatment of epilepsy in intellectually disabled patients is not essentially different from treatment in intellectually normal patients, 6 but the severity of their epilepsy often requires administration of multiple anti-epileptic drugs (AEDs), and frequently many (combinations of) products are started before seizure control is considered acceptable. However, a substantial proportion of patients, particularly those with severe intellectual disability, continue to suffer from poorly controlled seizures despite the use of two or more AEDs.
Purpose: To assess the long-term usefulness of 'new anti-epileptic drugs (AEDs)' (lamotrigine, topiramate, levetiracetam, gabapentin and pregabalin) in institutionalized intellectually disabled patients. Information from RCTs is lacking in this population with severe intellectual and behavioural disabilities. Methods: Retrospective study. Data from the medical files and the pharmacy databases of 118 institutionalized intellectually disabled patients who had ever used at least one of the new AEDs were analyzed. The main evaluation parameters were the duration of use (using Kaplan-Meier survival estimates) and the reason for discontinuation (lack of efficacy, occurrence of adverse events, or both) of the new AEDs. Drug continuation was based on the evaluation of treatment results by experienced epileptologists, and not on fixed criteria. Results: New AEDs were generally tried only after a substantial number of other regimens (with classic AEDs) had failed. The most frequently used new AEDs were lamotrigine (68%) and levetiracetam (58%), followed by topiramate (28%) and gabapentin (8%). The 3-year retention rates were 70% (lamotrigine), 52% (levetiracetam), 51% (topiramate) and 33% (gabapentin). Discontinuation due to ''lack of efficacy'' occurred in 61% (topiramate), 60% (lamotrigine) and 42% (levetiracetam) of the cases. Discontinuation due to adverse events occurred in 42% (levetiracetam), 33% (topiramate) and 28% (lamotrigine). Conclusions: Treatment of epilepsy with new AEDs was quite often successful in this very therapyresistant population.
ß Recently a study has been published on the long-term use of the new AEDs gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine and topiramate in adult patients with chronic epilepsy and learning disabilities in a single UK institution. 22 From this study it was concluded that gabapentin and tiagabine had little impact on epilepsy treatment, whereas oxcarbazepine, levetiracetam, lamotrigine and topiramate were used for more than 2 years in 45-85% of the patients. In order to increase the amount of data on the use of new AEDs in intellectually disabled patients, we performed the present retrospective study in three institutions in the Netherlands. The aim of this study was to establish the long-term retention of new AEDs (i.e. registered in the Netherlands after 1996) in institutionalized intellectually disabled patients.
Materials and methods
The study was performed as a retrospective study on the use of new anti-epileptic drugs (new AEDs, defined as AEDs registered in the Netherlands since 1996) in institutionalized intellectually disabled patients in three Dutch centres in the Netherlands (De Amerpoort, Baarn; Sherpa, Baarn; Merwebolder, Sliedrecht and SOVAK, Terheijden, the Netherlands). There were about 1700 inhabitants in these institutions. All patients with epilepsy in these institutions are treated by a neurologist (JC, ME or GG) with special expertise in epilepsy (epileptologist). We included only those patients who had ever been treated with one of the new AEDs.
New AEDs were registered in the Netherlands in the following years:
Lamotrigine 1996
Topiramate 1999
Gabapentin 1999
Levetiracetam 2000
Pregabalin 2004
The only selection criterion for inclusion in the study was the current or past use of new AEDs. Oxcarbazepine was not considered a new AED, as it is frequently used as a -possibly less toxic -replacement for carbamazepine and not as an additional AED when seizure control is inadequate. 22 The main source of information in this study consisted of the patients medical files, which were routinely completed by attending neurologist. The patient charts were checked for completeness using the institutions pharmacy databases. Treatment of the patients reflected normal clinical practice without the use of a formal protocol. AEDs were continued when the neurologist (in close collaboration with the patients carers) noted a significant improvement in seizure control, without unacceptable adverse effects. The participating neurologists were reluctant to continue new AEDs if there was no substantial improvement in seizure control. Formal criteria for success based on seizure counts (such as a 50% reduction in seizure frequency) were not used, because in this setting reliable seizure counts are difficult to achieve and may not reflect improvement from a patients individual perspective.
Patients were seen at regular intervals according to their clinical needs. The review period covered all available data on AED use from the admission date to the institution (which may have been many years prior to the start of the study), until the cut-off date of 5 February 2007. Data were collected on patient characteristics (age, weight, sex), severity of intellectual disability (based on IQ estimates), use of concomitant medication for behavioural disorders, and current use and history of use of AEDs. The main evaluation parameters were the duration of use of the new AEDs and the reason for discontinuation (lack of efficacy, occurrence of adverse events, or both). The duration of use was analyzed using Kaplan-Meier survival estimates. A Kaplan-Meier survival life table was constructed and plotted for the retention of lamotrigine, topiramate, levetiracetam and gabapentin (no analysis was performed for pregabalin, since this compound was only registered in 2004 and its use was limited to very few patients). Duration of retention was calculated as the time between the start date and the stop date of the AED concerned. If patients were still taking the drug at the time of data collection, or if a patient had died during the observation period, the data were censored. The differences in retention rates obtained were analyzed statistically using a log rank test.
Results
A description of the study population of 118 patients is presented in Table 1 . Mean age of the patients was 38.7 years (S.D. = 12.1; range 9-61 years), with a mean weight of 61.6 kg (range 24-99 kg). A total of 85% of the patients had moderate to severe intellectual disability (based on IQ estimates). Seven patients (5 using lamotrigine and 2 using levetiracetam) died during the review period; none of the deaths was considered to be related to AED treatment. In addition, 4 patients (2 using lamotrigine and 2 using lamotrigine, topiramate and levetiracetam) were lost to follow-up. A small number of patients (n = 14; 11.9%) used co-medication for behavioural disorder(s), including benzodiazepines (n = 8), antipsychotics (n = 4) and antidepressants (n = 3). In addition to the newer AEDs, many patients continued using one of the classic AEDs, with carbamazepine and valproate being the most frequently used compounds (used by 58.8 and 43.0% of the patients, respectively). The longest follow-up was possible for patients using lamotrigine (almost 14 years in one case), since this AED became available in the mid-90s. Only 3 of the newer AEDs (lamotrigine, topiramate and levetiracetam) were used in a sufficient number of patients for adequate analysis; gabapentin and pregabalin were only used in 9 and 7 patients, respectively. Most of the patients had tried many different AEDs and many have also used more than one of the newer AEDs. Lamotrigine was started on average as the 6th AED (range 2-8). The other new AEDs were chosen at a later stage (median as 7th AED). This order of selection of newer AEDs is largely related to their year of introduction, though other factors may also have played a role. The dose regimens used were within the dose ranges recommended in the prescribing information.
The most frequently used new AEDs were lamotrigine and levetiracetam, which were started in 68 and 58% of the patients, respectively (see Table 2 ).
Retention rates were estimated with Kaplan-Meier survival analysis (Fig. 1) . It should be noted that the number of patients treated with gabapentin was very low, making the estimates less reliable. The 2-and 3-year retention rates of lamotrigine were the highest, with 75 and 70%, respectively. The 2-and 3-year retention rates of the other AEDs were 59 and 52% (levetiracetam), 63 and 51% (topiramate) and 44 and 33%, respectively (gabapentin).
A log rank test showed statistically significant differences for retention rates of LTG vs GBP (p = 0.02), and for LTG vs TPM (p = 0.04).
The retention rate is a composite marker of efficacy and safety. To investigate whether discontinuation of treatment was related to insufficient efficacy or occurrence of adverse events, the reasons for discontinuation were categorized as ''lack of efficacy'', ''occurrence of adverse events'', or ''both reasons combined/other reasons''. The frequency distribution of these reasons for discontinuation were different for lamotrigine, topiramate and levetiracetam (the number of patients using gabapentin and pregabalin were too small for accurate analysis). In the lamotrigine-treated patients ''lack of efficacy'' was more frequently the reason for discontinuation (60% of the cases), with a lower rate of discontinuation due to adverse events (28% of the cases), whereas in the levetiracetam-treated patients ''lack of efficacy'' and ''adverse events'' were each the cause for discontinuation in 42% of the cases (see Fig. 2 ). For topiramate these percentages were 61 and 33%, respectively.
The nature of the adverse events was not remarkable different from that in the intellectually normal population with epilepsy. Some adverse events were classified as being related to behaviour, mood or cognition (12 in patients using levetiracetam, 8 in patients using lamotrigine, 7 in patients using topiramate, 1 in a patient treated with topiramate and gabapentin and 1 in a patient using gabapentin).
Discussion
The optimal management of epilepsy with use of AEDs in intellectually disabled patients is challenging due to the severity of the epilepsy and the associated medical and psychiatric problems. 2, 4 Because RCTs in epilepsy for the intellectually disabled are lacking, post-marketing studies systematically assessing the usefulness of new AEDs are of interest. Our study shows that new AEDs were quite often useful in this therapy-resistant and substantially intellectually disabled population. Lamotrigine and levetiracetam were the most often used new AEDs. Three-year retention rates were comparable to those previously reported in patients with normal intellectual abilities and in intellectually disabled patients. 22, 27, 31 From a total of about 1700 patients living in the institutions participating in our study, we estimate that about 500 were using AEDs for epilepsy. The 118 patients who had ever used one of the new AEDs can be considered rather low, pointing to a conservative approach to epilepsy treatment in this population. At the time of this study, only carbamazepine, valproate and lamotrigine were recommended as first-line AEDs in the Dutch Guidelines for the treatment of epilepsy. 23 In a 2006 revision of these guidelines 24 oxcarbazepine was added as a first-line AED. Both versions of the guidelines 23, 24 state that there are no controlled studies with sufficient evidence to select a first-choice AED for add-on treatment.
In the present study choice of a particular new AED has been partly determined by the chronological availability of the products, though other factors, such as knowledge of the product (due to the extend of marketing), positive experience with the compound, and ideas about relative efficacy and safety may also have played a role. Patients starting treatment with the newest products are likely to have first been treated with the earlier registered new AEDs (e.g. lamotrigine) and may have been more therapy-resistant.
The most frequently used new AEDs were lamotrigine (started in 68% of the patients) and levetiracetam (started in 58% of the patients), followed by topiramate (started in 28% of the patients).
The relatively low use of topiramate, despite the fact that it was already registered in 1999, may be due to its reputation of increased toxicity in this patient population. 18 The limited use of gabapentin, which was also available since 1999, may be related to its reputation of low efficacy in intellectually disabled patients. 25 Few studies have addressed retention rates in this specific subpopulation of severely intellectually disabled patients with (intractable) epilepsy. In a publication by Simister et al. 22 on a similar specific population of intellectually disabled patients with epilepsy in the UK, comparable results were obtained, with 2-year retention rates of 57% (lamotrigine), 45% (topiramate) and 56% (levetiracetam). We found retention rates which were at least as good, confirming a fair chance of success when one of the new AEDs is tried in this therapy-resistant subpopulation. The retention rates obtained for lamotrigine and topiramate in our study are slightly higher than those reported in other series of patients with epilepsy. An important difference between these series and ours is the exclusive selection of cases with severe intellectual disability in our series. Others reported retention rates for lamotrigine of 40-60% (after 1 year) and 29% (after 3 years), 26, 27 and for topiramate of 40-60% (after 1 year), 45% (after 2 years), 30-38% (after 3 years) and 30% (after 4 years). [26] [27] [28] [29] For levetiracetam the retention rates in the general population were similar to those obtained in our study, viz. 60-75% (after 1 year), 58% (after 3 years) and 32% (after 5 years). 26, 30, 31 Recently Chung et al. reported remarkably high retention rates for lamotrigine at 2 years (74%), with rates for topiramate (44%) and levetiracetam (54%) more in line with other studies. 32 Bootsma et al. compared retention rates for lamotrigine at 1 (74%) to 4 years (56%), and found that patients with normal cognitive function were more likely to continue the drug than patients with metal retardation. 33 From the same tertiary epilepsy centre, retention rates for levetiracetam (46%) and topiramate (38%) at 2 years were reported. 34 The high retention rates for levetiracetam and topiramate in our group of severely intellectually disabled patients may be due to more severe epilepsies with greater need for additional seizure suppression, better tolerance (or greater likelihood of missing cognitive and other adverse effects), and/or more specialized neurological care. As in the most published long-term follow-up studies the effects of the new AEDs on seizure control were not quantified by calculation of reductions in seizure frequency. Especially in this population seizure counts may be very unreliable, and may not reflect the impact on a patients individual functioning or quality of life. Although in this study retention ultimately was based on one neurologist's subjective assessment, in our view it reflects the best possible clinical practice.
Some differences in the reasons for discontinuation of new AEDs were observed. Lamotrigine and topiramate were discontinued due to lack of efficacy in 60 and 61% of the cases, whereas in the levetiracetam-treated patients this occurred in only 42% of the cases. Discontinuation because of adverse events occurred more frequently in the levetiracetam-treated patients (42% of the cases), compared to 33% in the topiramate-treated patients and 28% in the lamotrigine-treated patients. The incidence of adverse effects induced by topiramate does not confirm the reputation of topiramate of having a relatively high toxicity in intellectually disabled patients, 18 and is also not in line with the relatively high incidence of adverse events reported in the publications by Simister et al. 22 and Bootsma.et al. 28 We may have used topiramate more cautiously than others, using low dosages (mean 78 mg/day or 1.2 mg/kg) and slow titrations schedules, thus achieving higher retention rates.
Retrospective studies have obvious limitations. The open, nonrandomized design makes it impossible to definitely attribute observed improvements or adverse effects to the AED used, or to make meaningful head-to-head comparisons between new AEDs. Major strengths of this study were its resemblance to the normal clinical situation (there were no specific selection criteria for inclusion or schedules for treatment) and the quality of the documentation (records being kept for long periods of time; a stable study population with very few patients lost to follow-up). The effects of confounding factors such as severity of intellectual disability, the number and types of previously used AEDs, the number and types of currently used AEDs, use of concomitant (psychotropic or other medication) and age on the retention rates of the new AEDs were beyond the scope of this study.
The present study describes the usefulness of new AEDs in intellectually disabled patients in clinical practice. The calculated retention rates, which represent a composite measure of efficacy and safety over time, are relevant in assessing the value of a particular AED treatment. 35 We conclude that in this population a history of failure of a substantial number of (classical) AED regimens should not result in therapeutic nihilism.
